

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

**UNAUDITED FINANCIAL INFORMATION OF
CSPC INNOVATION PHARMACEUTICAL CO., LTD.
FOR THE THREE MONTHS ENDED 31 MARCH 2026**

In compliance with the relevant requirements of Shenzhen Stock Exchange, CSPC Innovation Pharmaceutical Co., Ltd. (“**CSPC Innovation**”), a subsidiary of CSPC Pharmaceutical Group Limited (the “**Company**”) listed on the ChiNext Market of Shenzhen Stock Exchange (Stock Code: 300765), published its unaudited first quarterly report for the three months ended 31 March 2026 (the “**2026 First Quarterly Report**”) on 27 April 2026 on the information disclosure webpage of Shenzhen Stock Exchange’s website at <http://www.szse.cn/disclosure/listed/notice/index.html>. CSPC Innovation’s financial information was prepared in accordance with the China Accounting Standards for Business Enterprises.

Set out in the appendices to this announcement (the “**Appendices**”) is the principal financial data of CSPC Innovation extracted from the 2026 First Quarterly Report prepared in Chinese. In case of any inconsistency between the Chinese version and the English version, the Chinese version shall prevail.

Shareholders and potential investors of the Company are reminded that the financial information of CSPC Innovation in the 2026 First Quarterly Report and in the Appendices are unaudited consolidated financial information of CSPC Innovation for the three months ended 31 March 2026, rather than that of the Company. They should exercise caution when dealing in the securities of the Company.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 27 April 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.

APPENDIX I

KEY ACCOUNTING DATA AND FINANCIAL INDICATORS

Currency: RMB

	Current reporting period	Corresponding period of the last year	Increase/decrease of the current reporting period compared to the corresponding period of the last year (%)
Revenue (Yuan)	664,646,761.85	471,967,670.63	40.82%
Net profit attributable to shareholders of the listed company (Yuan)	-93,854,748.19	-26,901,607.29	-248.88%
Net profit attributable to shareholders of the listed company after deducting non-recurring profit or loss (Yuan)	-111,071,889.68	-30,636,078.09	-262.55%
Net cash flow generated from operating activities (Yuan)	-179,519,773.88	-86,799,597.52	-106.82%
Basic earnings per share (Yuan/share)	-0.0674	-0.0192	-251.04%
Diluted earnings per share (Yuan/share)	-0.0674	-0.0192	-251.04%
Weighted average return on net assets	-3.58%	-0.72%	-2.86%
	At the end of the current reporting period	At the end of the last year	Increase/decrease at the end of the current reporting period compared to the end of the last year (%)
Total assets (Yuan)	6,210,002,233.37	6,276,311,291.82	-1.06%
Equity attributable to shareholders of the listed company (Yuan)	2,577,035,104.62	2,667,343,683.63	-3.39%

APPENDIX II

NON-RECURRING PROFIT OR LOSS ITEMS AND AMOUNTS

Unit: Yuan Currency: RMB

Item	Amount for the current reporting period	Description
Gains/losses on disposal of non-current assets (including the portion offset with the provision for impairment of assets)	-18,577.10	
Government grants recognised in profit or loss for the current period (excluding those closely related to the company's normal business operations, complying with national policies, granted according to established standards, and continuously affecting the company's profit or loss)	19,662,171.15	
Profit or loss from changes in fair value of financial assets and financial liabilities and profit or loss from disposal of financial assets and financial liabilities held by non-financial enterprises, other than effective hedging activities related to normal business operations of the company	2,730,414.01	
Non-operating income and expenses other than the items above	-1,199,068.51	
Less: Impact of income tax	91,732.61	
Impact of minority interests (after tax)	3,866,065.45	
Total	17,217,141.49	-

APPENDIX III

CHANGES IN AND REASONS FOR CHANGES IN KEY ACCOUNTING DATA AND FINANCIAL INDICATORS

Unit: Yuan Currency: RMB

1. Major items of consolidated balance sheet

Items	31 March 2026	31 December 2025	Changes	Reasons for changes
Trade receivables	597,579,995.72	441,330,765.53	35.40%	Mainly due to the increase in trade receivables resulting from revenue growth during the reporting period.
Other receivables	16,699,341.01	10,694,133.01	56.15%	Mainly due to the increase in dividends receivable from associate companies during the reporting period.
Other non-current assets	31,492,539.62	104,282,963.65	-69.80%	Mainly due to the decrease in prepayments for construction projects during the reporting period.
Long-term borrowings	10,000,000.00	—	N/A	Mainly due to the additional bank loans during the reporting period.

2. Major items of consolidated income statement

Items	January to March 2026	January to March 2025	Changes	Reasons for changes
Revenue	664,646,761.85	471,967,670.63	40.82%	Mainly due to the increase in revenue from functional ingredients and biopharmaceutical products during the reporting period, as well as the recognition of US\$10 million in revenue upon achieving an R&D milestone under the out-licensing collaboration for Megalith Biopharma's SYS6002.
Operating costs	391,166,567.77	283,552,644.93	37.95%	Mainly due to the increase in revenue from functional ingredients and biopharmaceutical products during the reporting period, resulting in a corresponding rise in costs.
Administrative expenses	29,783,566.02	18,984,758.44	56.88%	Mainly due to the increase in personnel costs for management staff, as well as the increase in depreciation resulting from the transfer of the comprehensive service building to fixed assets during the reporting period.
Research and development expenses	273,278,688.55	240,479,825.00	13.64%	Mainly due to the increase in R&D and innovation investment by Megalith Biopharma during the reporting period.
Finance costs	20,789,799.46	-14,536,544.36	243.02%	Mainly due to the appreciation of the RMB against the US dollar during the reporting period, resulting in an increase in foreign exchange losses.
Other gains	19,858,920.01	4,330,833.52	358.55%	Mainly due to the increase in government grants recognized by Megalith Biopharma during the reporting period.
Net profit attributable to shareholders of the listed company	-93,854,748.19	-26,901,607.29	-248.88%	Mainly due to factors such as the expanded consolidation scope of Megalith Biopharma (increase in shareholding ratio from 51% to 80%), increased R&D investment, and foreign exchange losses during the reporting period.

3. Major items of consolidated statement of cash flows

Items	January to March 2026	January to March 2025	Changes	Reasons for changes
Net cash flow generated from operating activities	-179,519,773.88	-86,799,597.52	-106.82%	Mainly due to the increase in expenses related to raw material procurement and R&D activity services.
Net cash flow generated from investing activities	-70,928,522.92	361,108,752.50	-119.64%	Mainly due to the decrease in the company's purchases of bank structured deposits during the reporting period compared to the last year.
Net cash flow generated from financing activities	110,466,338.50	163,000,000.00	-32.23%	Mainly due to the decrease in financial assistance received by Megalith Biopharma from the controlling shareholder during the reporting period compared to the corresponding period of the last year.